Anika Therapeutics (ANIK) Other Non-Current Liabilities (2010 - 2026)
Anika Therapeutics (ANIK) posted quarterly Other Non-Current Liabilities of $730000.0 for Q2 2026, down 3.44% year-over-year from $756000.0 in Q2 2025, and up 0.55% quarter-over-quarter from $726000.0 in Q1 2026.
Anika Therapeutics (ANIK) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has reported Other Non-Current Liabilities for 17 consecutive years, with $730000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non-Current Liabilities fell 3.44% year-over-year to $730000.0; the TTM figure through Jun 2026 stood at $730000.0 (down 3.44% YoY), while the FY2025 annual figure was $701000.0, down 9.2% from the prior year.
- Other Non-Current Liabilities grew to $730000.0 in Q2 2026 per ANIK's latest filing, from $726000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $806000.0 in Q3 2024 and bottomed at $398000.0 in Q4 2022.
- Historically, Other Non-Current Liabilities has averaged $586333.3 across 5 years, with a median of $635500.0 in 2022.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities slumped 96.53% — and 2024, when it jumped 101.5%.
- Anika Therapeutics' Other Non-Current Liabilities stood at $398000.0 in 2022, then advanced by 1.51% to $404000.0 in 2023, then surged by 91.09% to $772000.0 in 2024, then slipped by 9.2% to $701000.0 in 2025, then rose by 4.14% to $730000.0 in 2026.
- Business Quant data shows ANIK's Other Non-Current Liabilities at $730000.0 in Q2 2026, $726000.0 in Q1 2026, and $701000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Anika Therapeutics | 285.40 Mn | 246.98 Mn | 21.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 730,000.00 |
| Mar 31, 2026 | 726,000.00 |
| Dec 31, 2025 | 701,000.00 |
| Sep 30, 2025 | 761,000.00 |
| Jun 30, 2025 | 756,000.00 |
| Mar 31, 2025 | 744,000.00 |
| Dec 31, 2024 | 772,000.00 |
| Sep 30, 2024 | 806,000.00 |
| Jun 30, 2024 | 407,000.00 |
| Mar 31, 2024 | 404,000.00 |
| Dec 31, 2023 | 404,000.00 |
| Sep 30, 2023 | 400,000.00 |
| Jun 30, 2023 | 401,000.00 |
| Mar 31, 2023 | 399,000.00 |
| Dec 31, 2022 | 398,000.00 |
| Sep 30, 2022 | 474,000.00 |
| Jun 30, 2022 | 587,000.00 |
| Mar 31, 2022 | 684,000.00 |
| Dec 31, 2021 | 1.26 Mn |
| Sep 30, 2021 | 1.49 Mn |